{"id":"W3031480296","doi":"10.1200/jco.2020.38.15_suppl.tps6108","title":"DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Carboplatin; PARP inhibitor; Cancer; Ovarian cancer; Bevacizumab; Hazard ratio; Atezolizumab; Nivolumab; Chemotherapy; Immunotherapy; Cisplatin; Confidence interval; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001375728,0.001544492,0.001604278,0.0003611267,0.0003002417,0.001103304,0.001087444,0.001564585,0.01185493],"category_scores_gemma":[0.0009632757,0.0006226033,0.001382443,0.0003270282,0.0008639811,0.0009501983,0.0003817489,0.003565788,0.001916785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001155481,"about_ca_system_score_gemma":0.001429672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001585005,"about_ca_topic_score_gemma":0.006809708,"domain_scores_codex":[0.9996901,0.0001515639,0.0000125138,0.00005362049,0.00002509078,0.00006708899],"domain_scores_gemma":[0.9995878,0.00007627842,0.0000706619,0.0000315933,0.00002577963,0.0002078521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9273546,0.01669536,0.00107266,0.0009666565,0.001042053,0.00007976087,0.00008699891,0.0007067635,0.004978304,0.0004701606,0.005407813,0.04113884],"study_design_scores_gemma":[0.952503,0.04297138,0.001199502,0.0000432382,0.0002762613,0.00005604481,0.00002935475,0.0005102597,0.0003010548,0.0002692532,0.001827625,0.00001313065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9700195,0.007934611,0.0008738036,0.002696109,0.00123049,0.00641554,0.003614578,0.0003665747,0.006848812],"genre_scores_gemma":[0.9595166,0.005475699,0.002651285,0.004339099,0.0003920644,0.007914249,0.004981309,0.00008455341,0.01464508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01185493,"threshold_uncertainty_score":0.03965867,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06261902169067038,"score_gpt":0.4049392146227062,"score_spread":0.3423201929320359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}